IRAK4 and Pruritus: The marked improvement in pain and/or pruritus that we observed in patients with HS and patients with AD treated with KT-474 for a relatively short period of time also raises the possibility that IRAK4 degradation could be modifying those symptoms via a neuro-immune mechanism in conjunction with its impact on skin lesion inflammation.